NAUT (Nautilus Biotechnology) Buildings And Improvements : $27.10 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Buildings And Improvements?

Nautilus Biotechnology's quarterly buildings and improvements declined from Sep. 2024 ($29.38 Mil) to Dec. 2024 ($28.26 Mil) and declined from Dec. 2024 ($28.26 Mil) to Mar. 2025 ($27.10 Mil).

Nautilus Biotechnology's annual buildings and improvements increased from Dec. 2022 ($28.87 Mil) to Dec. 2023 ($32.63 Mil) but then declined from Dec. 2023 ($32.63 Mil) to Dec. 2024 ($28.26 Mil).

Nautilus Biotechnology Buildings And Improvements Historical Data

The historical data trend for Nautilus Biotechnology's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Buildings And Improvements Chart

Nautilus Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

4.84

28.87

32.63

28.26

Nautilus Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial															-	30.47	29.38	28.26	27.10

Nautilus Biotechnology Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Nautilus Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

2701 Eastlake Avenue East, Seattle, WA, USA, 98102

Website

https://www.nautilus.bio

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

Executives

Parag Mallick	director, 10 percent owner, officer: Chief Scientist	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Sujal M Patel	director, 10 percent owner, officer: CEO, President, and Secretary	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin	officer: Senior VP, Operations	3101 WESTERN AVENUE, SEATTLE WA 98121
Michael Seth Altman	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar	officer: Senior VP, Product Development	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld	officer: Chief People Officer	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry	officer: CFO and Treasurer	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy	officer: General Counsel	C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Karen Akinsanya	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Advisors Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain	director	1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Ah Bio Fund Ii-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025